Johnson & Johnson: Time To Buy Before The Split


  • JNJ will be spinning off its popular consumer health segment into a separate company called Kenvue.
  • Medical Devices and Pharmaceutical segments will remain together in which they are the fastest growing segments within the business.
  • In a time of much uncertainty surrounding 2023, JNJ is a defensive name with essential products with a rock-solid dividend.

Generic brand pain medication vs name brand Tylenol. Pain relief.

CatLane/iStock Unreleased via Getty Images

Johnson & Johnson (NYSE:JNJ) for years has been a safety net for many dividend investors, and that continues to be the case in 2022. In a year in which the S&P 500 (



Seeking Alpha

Fast Graphs

Disclosure: I/we have a beneficial long position in the shares of JNJ, ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

No marketing to add

Leave a Reply

Your email address will not be published. Required fields are marked *